WARPTECHNEWS · LAB
HomeAIBusinessTechArchive
WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

  • Home
  • Archivio
  • Editor's Brief
  • Cerca
  • Il tuo account
  • Newsletter tech/AI

Informazioni legali

  • Privacy Policy
  • Termini di servizio
  • Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Home
Storia in 2 fonti

Bristol Myers, Hengrui join forces in drugmaking alliance worth up to $15.2 billion

The wide-ranging pact involves as many as 13 drugs and marks the latest example of the growing relationship between Chinese pharmaceutical firms and their U.S. and Europe-based counterparts.

Raccontata dabiopharmadive.comendpoints.news

Confronto fonti

2 prospettive sulla stessa storia
AI · summaries
biopharmadive.comStai leggendo1 mesi fa

Bristol Myers, Hengrui join forces in drugmaking alliance worth up to $15.2 billion

The wide-ranging pact involves as many as 13 drugs and marks the latest example of the growing relationship between Chinese pharmaceutical firms and their U.S. and Europe-based counterparts.

originale
endpoints.news1 mesi fa

Bristol Myers joins Hengrui party in 13-asset deal worth up to $15.2B

Hengrui Pharma has lined up Bristol Myers Squibb as its latest partner in a deal worth up to $15.2 billion. The total value of the pact marks one of the largest East-to-West cross-border deals in industry history.

Leggi questa versione →

Timeline cronologica

  1. martedì 12 maggio 2026·biopharmadive.com

    Bristol Myers, Hengrui join forces in drugmaking alliance worth up to $15.2 billion

    The wide-ranging pact involves as many as 13 drugs and marks the latest example of the growing relationship between Chinese pharmaceutical firms and their U.S. and Europe-based…

  2. martedì 12 maggio 2026·endpoints.news

    Bristol Myers joins Hengrui party in 13-asset deal worth up to $15.2B

    Hengrui Pharma has lined up Bristol Myers Squibb as its latest partner in a deal worth up to $15.2 billion. The total value of the pact marks one of the largest East-to-West…

originale